Dr. Frattini has over 20 years of experience in the field of hematological malignancies and joined
Cellectis in August 2020 as Senior Vice President of Clinical Sciences where he has been
responsible for Cellectis’ clinical leadership including the clinical development strategy of the
Company’s current immune-oncology UCART product candidates. He has also been serving as a
core member of the senior clinical team. In September 2022, Dr. Frattini was appointed Cellectis’
Chief Medical Officer. As Chief Medical Officer, Dr. Frattini oversees clinical research and
development for Cellectis’ UCART clinical trial programs.
Prior to joining Cellectis, Dr. Frattini was Executive Medical Director, Program Lead, Global Clinical
Research & Development at Celgene/Bristol Myer Squibb and was responsible for the oversight
and management of several of Celgene’s sponsored programs in the hematology therapeutic
area. Before joining Celgene, Dr. Frattini spent over 16 years as a physician-scientist specializing
in hematologic malignancies in academia at Memorial Sloan-Ketering Cancer Center and
Columbia University where he was a member of the adult leukemia service and the Experimental
Therapeutics center at both institutions. At Columbia University from 2013-2018 Mark also
served as the Director of Research for Hematologic Malignancies.
Dr. Frattini holds a M.D. and Ph.D. in Biochemistry and Molecular Biology from The University of
Chicago and received his Internal Medicine residency and Medical Oncology fellowship training
at Johns Hopkins Hospital.